VANCOUVER, British Columbia, Jan. 06, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is pleased to announce that it has engaged Image Analysis Group (IAG), a leading medical imaging company, to provide important critical imaging services during the Berubicin phase 2 clinical trials which are scheduled to start in February 2021.

IAG has deep expertise in partnering with global biotech companies to provide centralized reading and analysis of patient responses in real time. IAGs scientific and clinical imaging expertise in the field ofglioblastomamultiforme (GBM), coupled with IAGs proprietary Artificial Intelligence (AI) powered platform DYNAMIKA will allow WPD and its partners to review efficacy assessments, objective responses, and to thoroughly explore Berubicins effect in patients with GBM.

Advanced cancer therapies often lead to pseudo-progression, a local tissue reaction resulting from immune cell infiltration, causing inflammation, tumor necrosis and oedema which are often misinterpreted as tumor growth on traditional MRIs. Under the arrangement, IAG will utilize its advanced AI-driven methodologies that provide reliable early efficacy readouts. Pseudo-progression is difficult to distinguish from disease progression using routine clinical MRI assessments, and having IAGs advanced technology will be crucial for early detection and progression.

Mariusz Olejniczak, CEO of WPD commented, We are very pleased to partner with IAG to collaborate on the upcoming Berubicin trials and other studies including WPD101, if possible in the future. IAG has a strong track record of working with leading biotech companies to provide critical imaging collection, analysis, and assessment which is a very important part of our Berubicin phase 2 trials. We look forward to working with them leading up to and in preparation of the commencement of these Trials.

Olga Kubassova, CEO of IAG commented, We are pleased that IAGs unique focus on the use of quantitative imaging and AI will help accelerate WPDs development programs while reducing R&D costs, timelines, and uncertainties. This work will support the field of advanced cancer drug development as a whole and provide much needed treatment options to patients with glioblastoma.

Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG commented, The integration of advanced imaging and AI driven image analysis will prevent a false response assessment in patients experiencing pseudo-progression and thereby enhance the efficacy read out of Berubicin, avoid early patient drop-out and save costs. IAG is excited to collaborate with WPD and to support the clinical development with optimal imaging trial design, efficient imaging data management and response assessment.

About Image Analysis Group

Image Analysis Group (IAG) is a unique clinical development partner to life sciences companies. IAG broadly leverages its proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. IAGs independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.

On Behalf of the Board

Mariusz Olejniczak

Mariusz Olejniczak CEO, WDP Pharmaceuticals

Contact:

Investor Relations Email: investors@wpdpharmaceuticals.com Tel: 604-428-7050 Web: http://www.wpdpharmaceuticals.com

Cautionary Statements:

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that IAGs technology will enhance our analysis of the effects of Berubicin, that we may partner with IAG regarding our other compounds and that WPDs drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Companys current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that the IAG technology may not provide the benefits expected and we may not engage them further; competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded; that our drugs dont provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at http://www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

See the article here:
WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin -...

The National Defense Authorization Act for the Fiscal Year 2021 (2021 NDAA)which was passed over a Presidential veto on January 1represents a massive step forward for American AI policy in areas far beyond national defense. It incorporates a number of AI legislative proposals that will reshape the governments approach over the next two years, as part of a broader emphasis on promoting emerging technologies.

Among its many elements, the 2021 NDAA (1) expands National Institute of Standards and Technologys (NIST) AI responsibilities, including directing it to establish a voluntary risk management frameworkin consultation with industrythat will identify and provide standards and best practices for assessing the trustworthiness of AI and mitigating risks from AI systems; (2) launches the National Artificial Intelligence Initiative, setting up a federal bureaucracy designed to deal both with agencies and outside stakeholders, as well as advise on key issue issues of AI implementation like bias and fairness; (3) gives the Department of Defense (DoD) specific authority to procure AI while requiring an assessment meant to promote acquisition of AI that is ethically and responsibly developed.All of these initiatives will have ripple effects on private sector development, testing, and deployment of AI systemsand heavily influence regulatory expectations on issues like AI bias, accuracy, and security.

Below is a high-level summary of these key AI provisions.

NIST Is Required to Development a Risk Management Framework for Use in Implementing AI

The NDAA gives NIST specific direction and deadlines for developing a risk management framework for use of AI and defining measurable standards that can be used within the framework.NIST already has been very active on AI issues, particularly following the 2019 AI Executive Order.The NDAA expands NISTs AI responsibilities through a specific legislative mandate on AI, placing the agency at the center of working through critical issues involving bias, privacy, security, transparency, and even ethics.And while this directive will result in a risk framework that will be voluntary, NISTs work in similar areas like cybersecurity has proven enormously influential to the private sector and has been closely monitored by policymakers.

Specifically, the NDAA amends the National Institute of Standards and Technology Act to give NIST four distinct missions with respect to AI:

Advancing collaborative frameworks, standards, guidelines, and associated methods and techniques for AI;

Supporting the development of a risk-mitigation framework for deploying AI systems;

Supporting the development of technical standards and guidelines that promote trustworthy AI systems; and

Supportingthe development of technical standards and guidelines by which to test for bias in AI training data and applications.

It directs NIST to develop an AI risk management framework within two years.The framework must include standards, guidelines, procedures, and best practices for developing and assessing trustworthy AI and mitigating risks related to AI. NIST also must establish common definitions for elements of trustworthiness, including explainability, transparency, safety, privacy, security, robustness, fairness, bias, ethics, validation, verification, and interpretability.This mandate aligns with NISTs ongoing work regarding trustworthy AI, but importantly, it provides a more definite timeline and specific elements for the framework.It also makes clear that NIST should work to develop common definitions related to range of complex issues like bias and transparencyand even ethics and fairness, which are not usually within NISTs ambitthat could have broader implications if adopted by regulatory bodies concerned with potential adverse effects of AI.

Additionally, the NDAA requires NISTwithin a yearto develop guidance to facilitate the creation of voluntary AI-related data sharing arrangements between industry and government, and to develop best practices for datasets used to train AI systems, including standards for privacy and security of datasets with human characteristics.The guidance around datasets will have particular importance for mitigating bias that can result from AI making use of data that is not representative.

NIST has a long history of collaborating with industry stakeholders on key issues, including cybersecurity and privacy, and its AI work to date has followed this collaborative approach.Indeed, NIST is planning a virtual workshop on Explainable AI later this month.With NISTs newly expanded role, AI stakeholders will have multiple additional opportunities to engage.

The National Artificial Intelligence Initiative Is Launched with a New Bureaucratic Framework.

The NDAA instructs the President to establish the National Artificial Intelligence Initiative and provides a framework for its implementation throughout the federal government.The focus of this Initiative will be to ensure continued U.S. leadership in AI R&D and the development and use of trustworthy artificial intelligence systems; to prepare the U.S. workforce for integration of AI; and to coordinate AI R&D among civilian, defense, and intelligence agencies.

To implement the Initiative, the law establishes a bureaucratic framework for dealing with AI within the government, complementing efforts that previous Administrations have made without a legislative mandate.These include:

The National Artificial Intelligence Initiative Office.This Office will be housed within the White Houses Office of Science and Technology Policy (OSTP) and will serve as an external and internal contact on AI, conduct outreach, and act as agency hub for technology and best practices.

An AI Interagency Committee.The Interagency Committeeto be co-chaired by the Director of the OSTP and, on an annual rotating basis, a representative from the Department of Commerce, the National Science Foundation, or the Department of Energywill coordinate Federal programs and activities in support of the National Artificial Intelligence Initiative.

The National Artificial Intelligence Advisory Committee.This Advisory Committeeto be established by the Department of Commerce in consultation with a slate of other federal stakeholderswill include members with broad and interdisciplinary expertise and perspectives, including from academic institutions, nonprofit and civil society entities, Federal laboratories, and companies across diverse sectors. It will provide recommendations related to, among other things, whether ethical, legal, safety, security, and other appropriate societal issues are adequately addressed by the Initiative, and accountability and legal rights, including matters relating to oversight of AI using regulatory and nonregulatory approaches, the responsibility for any violations of existing laws by an AI system, and ways to balance advancing innovation while protecting individual rights.It also will include a subcommittee on AI in law enforcement that will advise on issues of bias (including use of facial recognition), security, adoptability, and legal standards including privacy, civil rights, and disability rights.

This Initiative also presents an opportunity for private sector engagement.The Initiatives many priorities include coordinating R&D and standards engagement and providing outreach to diverse stakeholders, including citizen groups, industry, and civil rights and disability rights organizations.In particular, the National Artificial Intelligence Advisory Committee is required to include industry representatives as it makes recommendations on key issues including AI oversight by the government.

DoD Is Directed to Assess Its Ability to Acquire Ethically and Responsibly Developed AI Technology.

The NDAA provides the Department of Defenses (DoD) Joint Artificial Intelligence Center (JAIC) with authority to acquire AI technologies in support of defense missions.Additionally, it puts into place procedures to ensure that DoD acquires AI that is ethically and responsibly developed and that it effectively implements ethical AI standards in acquisition processes and supply chains.

Specifically, the NDAA requires the Secretary of Defense to conduct an assessment to, among other things, determine whether DoD has the ability, resources, and expertise to ensure that the AI it acquires is ethically and responsibly developed.The assessment must be completed within 180 days, and following that, the Secretary must brief the Congressional committees as to the results.

These provisions will impact DoD procurement and contractors, and given the size and scope of the Defense acquisition budget, will also likely impact private sector development of AI to meet ethical and responsible standards.

***

AI technology has been an area of increased focus of the federal government in the past several years, most notably following 2019 and 2020 AI Executive Orders.The new efforts launched by the 2021 NDAA add to existing work and make clear that AI will be a continued focus of federal government activity.

Follow this link:
Federal AI Efforts Will Be Greatly Boosted by 2021 NDAA - JD Supra

HERNDON, Va.--(BUSINESS WIRE)--BlackSky, a leading provider of global monitoring services and geospatial insights, today announced an award from the Intelligence Advanced Research Projects Activity (IARPA) for a multi-phase, multi-year research contract. IARPA is responsible for leading research programs to overcome difficult challenges relevant to the U.S. intelligence community.

BlackSky has been selected to aid in the development of IARPAs Space-based Machine Automated Recognition Technique (SMART) Program. The SMART program aims to automate the quantitative analysis of space-based imagery to perform broad-area searches for natural and man-made events using time-series imagery. BlackSky will expand upon its Spectra AI platform to develop a responsive system that can automatically monitor large-scale construction of critical infrastructure such as military bases, stadiums, campuses, dams, and airports.

This is a tremendous breakthrough in unsupervised learning for our Spectra AI platform and an unprecedented step toward the future of global monitoring, said Brian OToole, CEO of BlackSky. The IARPA SMART program is a natural fit for BlackSky given our deep expertise in geospatial analytics and our proven ability to deliver first-to-know insights.

Under the contract, BlackSky will create open source, supervised, and semi-supervised learning algorithms to recognize data patterns specific to large-scale construction projects. The combined effort will leverage the resources of NASAs and U.S. Geological Survey Landsats constellation and Sentinel, the European space agencys constellation.

About BlackSky LLC

BlackSky is a global monitoring company. We monitor activities and facilities worldwide by harnessing the worlds emerging sensor networks and leveraging our own satellite constellation. We process millions of observations daily from space, air, environmental sensors, asset tracking sensors, Industrial IoT, and Internet-enabled narrative sources. BlackSkys on-demand swarm of satellites can image a location multiple times throughout the day. We monitor for pattern-of-life anomalies to produce alerts and enhance situational awareness. Our monitoring service is powered by cutting-edge compute techniques including machine learning, artificial intelligence, computer vision, and natural language processing. BlackSkys global monitoring is available via a simple subscription and requires no IT infrastructure or setup. For more information visit http://www.blacksky.com

Read more from the original source:
BlackSky Awarded IARPA Contract to Develop Platform for Global Construction Monitoring Using Next Generation Artificial Intelligence - Business Wire

When people hear the word artificial intelligence, most of us are tend to think about the atrocious robot that takes over humankind asportrayed in sci-fi movies. Even though it is possible whenAI reaches a certain level of improvement, the current developments in technology are mostly human-friendly. Artificial intelligence refers to the simulation of human intelligence in machines programmed to think like humans and mimic their actions. Generally,AI benefits in significant fieldslike finance, healthcare, business, and security. Besides, humans can never beat AI in weather prediction, drug discovery, and stock market crashes. We are alreadyemploying AI to do many jobsin our daily routine. For example, Netflix and Spotify use AI technology to sort the viewers preference. A lot of modern home appliances are powered by AI. Henceforth, let us take a moment to think about some extraordinary things that AI is doing today. Analytics Insight brings you a list of AI applications that shows the power of AI.

We always had a thought on how AI will react if it can hear, taste, or smell things. Scientists and researchers have been working to improve such features in AI machines. Even though it is a long way to reach that stage, tech companies are taking baby steps to improve relative technologies. IBM research is collaborated with a German Fragrance House Symrise to introduce artificial olfaction sensation in the perfume industry. They analyzed present fragrance chemical formulas to develop a new way of preparing fragrances. The companies used data to sort consumer choices and preferences by studying historical buying options. Later, they used the data to mix several aromatic components to give people a unique fragrance. In 2019, two AI-prepared aromas were released by the company.

Pet lovers, please take note. AI pets are stealing the market with more love. Generally, children play with cyborg dogs and little robots. It was not a big deal until the real AI pet entered the tech space. AI pets can recognize emotions and respond to your commands. Yes, it is very heartwarming. MOFLIN is an AI pet with emotional capabilities. It evolves like living animals. MOFLIN is designed to learn and constantly grow, using its interactions to determine patterns and evaluate its surroundings from its sensors. The AI pet chooses from an infinite number of mobile and sound pattern combinations to respond and express their feelings.

Thinking AI as a fortune teller might sound funny. But the futuristic technology is bringing breakthrough changes into the modern landscape. AI researchers are working to make technology discover peoples feelings and emotions with high precision. Stanford University researchers unveiled an algorithm that scans faces on images to declare a person as gay. The AI algorithm is efficient enough to detect a gay with 81% accuracy in men and 74% accuracy in women. Social media platforms are also using AI to flag unusual behavior among people, leading to suicide. Facebooks AI detected over a hundred cases that needed attention.

We are at the technological evolution where AI is capable of showing its interest in art and creativity. Today, AI is composing music, drawing pictures and much more. An AI-based system called MuseNet can now compose classical music that echoes the classical legends, Bach and Mozart. OpenAIs MuseNet is a Deep Neural Network that can create four-minute musical compositions with different tech instruments and combine Mozarts country styles with the Beatles. An algorithm developed by Tao Xu at Microsoft Research generates art or pictures. It is trained on a database of photographs and descriptions, matching certain words to particular colors, textures, and shapes.

AI-powered robots are doing the cooking and serving jobs for a long time. Recently, chef robots have invaded the Chinese military to cook food for army men. However, an AI-machine designing the food you crave or suggesting a dish with the left-over ingredients is something to note. IBMs Chef Watson might be the solution home chefs need to overcome a pantry with only a few ingredients that couldnt possibly go together or welcome inspiration to professional chefs who want to evolve their menu through cognitive cooking and take advantage of seasonal ingredients.

We are familiar with how AI is invading every sector and transforming them for good. But we always thought that we are superior to AI in every way. Currently, AI can benefit the resume filtering process, which can be time-consuming and tedious. Even though there are minor issues like AI recruitment facing discrimination problems, the technology is updating its functionalities to conquer them. Besides, AI software can design interview questions for potential hires with a focus on the persons professional competency for a particular job without knowing their race, gender, or ethnicity.

Smart cities are the dream of both governments and people. Many countries worldwide are trying to turn their developing city into a smart city with Internet of Things (IoT) connectivity. According to Omdia, the global smart city AI software market is set to soar to US$4.9 billion in 2025, up from US$673.8 million in 2019. Wireless data communication standards are enabling smart city applications to move into the online realm where they can capitalize on the latest AI innovations.

Share This ArticleDo the sharing thingy

About AuthorMore info about author

Analytics Insight is an influential platform dedicated to insights, trends, and opinions from the world of data-driven technologies. It monitors developments, recognition, and achievements made by Artificial Intelligence, Big Data and Analytics companies across the globe.

Read this article:
Top 7 Amazing Artificial Intelligence Applications that Are Unfamiliar - Analytics Insight

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-in-medical-imaging-market&ab

Global Artificial Intelligence in Medical Imaging Market of which artificial intelligence in medical imaging is a part of is expected to rise from its initial estimated value of USD 21.48 billion in 2018 to a projected value of USD 264.85 billion by 2026, registering a CAGR of 36.89% in the forecast period of 2019-2026.

Global Artificial Intelligence in Medical Imaging Market Analysis:

Medical imaging can be described as the diagnostic procedure that involves the creation of visual aids and image representations of the human body, and involves the monitoring of performance and functioning of the organs of the human body. With the integration of artificial intelligence (AI) in healthcare and medical imaging, there is a change in the way the diagnostics and the entire procedure is carried out. The AI assists the surgeons in carrying out the image capturing process and how to diagnose these images for the conclusion and personalized treatment in respect to every individual and patient. Artificial intelligence mainly consists of two types, robots and machine learning. Machine learning involves the recognition and application of algorithm in computer systems for the rendering of images. Whereas, robots are engaged in the assistance of patients, doctors and operators in the visualization and diagnostic procedures.

Some of Key Competitors or Companies Included In the Study Are

BenevolentAIOrCamBabylon,Freenome IncClarify Health SolutionsBioXcel Therapeutics,Ada Health GmbHGNS HealthcareZebra Medical Vision IncQventus IncIDx Technologies IncK HealthPrognosMedopad Ltdai Inc.MobileSuki AI IncBERG LLCZealth IncCheck Complete Report Details (Including full TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-in-medical-imaging-market&ab

This Artificial Intelligence in Medical Imaging Market Research report focuses on numerous industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company. This report aims to deliver an opportunity for companies to recognize the modern trends size, growth, share, segments, manufacturers, and technologies, future road map and 2027 forecast. To attain actionable market insights to form sustainable and money-spinning business strategies with an ease, this market research report is a great option. A team of passionate analysts, skilled researchers and qualified forecasters work meticulously to generate such kind of market report. The credible Artificial Intelligence in Medical Imaging Market 2020 describes CAGR (compound annual growth rate) values and its fluctuations for the definite forecast period.

The report also evaluates other pivotal market aspects including revenue generated, demand and supply dynamics, market value, CAGR, pricing volatility, market share, import/export status, expenditure, and rates of production and consumption, among others. Numerous analytical tools have been employed in this report to predict the potential expansion of the market. The report gives market estimates derived by using both top-down and bottom-up approaches.

Market Segment by Types:-

By Offering (Hardware, Software, Services), Technology (Deep Learning, Computer Vision, NLP, Others)By Deployment Type (On-Premise, Cloud), Application (X-Ray, CT, MRI, Ultrasound, Molecular Imaging)By Clinical Applications (Breast, Lung, Neurology, Cardiovascular, Liver, Prostate, Colon, Musculoskeletal, Others)By End-User (Hospitals, Clinics, Research Laboratories, Others),Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2027) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:o North America (Covered in Chapter 6 and 13)o Europe (Covered in Chapter 7 and 13)o Asia-Pacific (Covered in Chapter 8 and 13)o Middle East and Africa (Covered in Chapter 9 and 13)o South America (Covered in Chapter 10 and 13)

Years considered for this report:o Historical Years: 2010-2019o Base Year: 2019o Estimated Year: 2020o Artificial Intelligence in Medical Imaging Market Forecast Period: 2020-2027

With tables and figures helping analyses worldwide Global Artificial Intelligence in Medical Imaging market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Some Points from TOC:1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Regulatory Scenario by Region/Country1.4 Market Investment Scenario Strategic1.5 Market Analysis by Type1.5.1 Global Artificial Intelligence in Medical Imaging Market Share by Type (2020-2027)1.5.2 Type 11.5.3 Type 21.5.4 Other1.6 Market by Application1.6.1 Global Artificial Intelligence in Medical Imaging Market Share by Application (2020-2027)1.6.2 Application 11.6.3 Application 21.6.4 Other1.7 Artificial Intelligence in Medical Imaging Industry Development Trends under COVID-19 Outbreak1.7.1 Region COVID-19 Status Overview1.7.2 Influence of COVID-19 Outbreak on Artificial Intelligence in Medical Imaging Industry Development

Global Market Growth Trends2.1 Industry Trends2.1.1 SWOT Analysis2.1.2 Porters Five Forces Analysis2.2 Potential Market and Growth Potential Analysis2.3 Industry News and Policies by Regions2.3.1 Industry News2.3.2 Industry Policies3 Value Chain of Artificial Intelligence in Medical Imaging Market3.1 Value Chain Status3.2 Artificial Intelligence in Medical Imaging Manufacturing Cost Structure Analysis3.2.1 Production Process Analysis3.2.2 Manufacturing Cost Structure of Artificial Intelligence in Medical Imaging3.2.3 Labor Cost of Artificial Intelligence in Medical Imaging3.3 Sales and Marketing Model Analysis3.4 Downstream Major Customer Analysis (by Region)

4 Players Profiles4.1 Player 14.1.1 Player 1 Basic Information4.1.2 Artificial Intelligence in Medical Imaging Product Profiles, Application and Specification4.1.3 Player 1 Artificial Intelligence in Medical Imaging Market Performance (2015-2020)4.1.4 Player 1 Business Overview4.2 Player 24.2.1 Player 2 Basic Information4.2.2 Artificial Intelligence in Medical Imaging Product Profiles, Application and Specification4.2.3 Player 2 Artificial Intelligence in Medical Imaging Market Performance (2015-2020)4.2.4 Player 2 Business Overview4.3 Player 34.3.1 Player 3 Basic Information4.3.2 Artificial Intelligence in Medical Imaging Product Profiles, Application and Specification4.3.3 Player 3 Artificial Intelligence in Medical Imaging Market Performance (2015-2020)4.3.4 Player 3 Business Overview4.4 Player 44.4.1 Player 4 Basic Information4.4.2 Artificial Intelligence in Medical Imaging Product Profiles, Application and Specification4.4.3 Player 4 Artificial Intelligence in Medical Imaging Market Performance (2015-2020)4.4.4 Player 4 Business Overview4.5 Player 54.5.1 Player 5 Basic Information4.5.2 Artificial Intelligence in Medical Imaging Product Profiles, Application and Specification4.5.3 Player 5 Artificial Intelligence in Medical Imaging Market Performance (2015-2020)

4.5.4 Player 5 Business Overview5 Global Artificial Intelligence in Medical Imaging Market Analysis by Regions5.1 Global Artificial Intelligence in Medical Imaging Sales, Revenue and Market Share by Regions5.1.1 Global Artificial Intelligence in Medical Imaging Sales by Regions (2015-2020)5.1.2 Global Artificial Intelligence in Medical Imaging Revenue by Regions (2015-2020)5.2 North America Artificial Intelligence in Medical Imaging Sales and Growth Rate (2015-2020)5.3 Europe Artificial Intelligence in Medical Imaging Sales and Growth Rate (2015-2020)5.4 Asia-Pacific Artificial Intelligence in Medical Imaging Sales and Growth Rate (2015-2020)5.5 Middle East and Africa Artificial Intelligence in Medical Imaging Sales and Growth Rate (2015-2020)5.6 South America Artificial Intelligence in Medical Imaging Sales and Growth Rate (2015-2020)

11 Global Artificial Intelligence in Medical Imaging Market Segment byTypes12 Global Artificial Intelligence in Medical Imaging Market Segment by Applications13 Artificial Intelligence in Medical Imaging Market Forecast by Regions (2020-2027)Continued

Get Free DetailedTOC@https://www.databridgemarketresearch.com/toc/?dbmr=global-artificial-intelligence-in-medical-imaging-market&ab

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

See the article here:
Artificial Intelligence in Medical Imaging Market 2020 Global Industry Size, COVID-19 Impact Analysis, Growth, Manufacturers, Segments and 2027...